News
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, Ekterly, for a type of ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
As Chinese-developed drugs draw U.S. interest, a regulatory chill threatens to dampen new investment
Those questions, experts say, are based on the Trump administration’s hawkish approach to China generally, as well as on a ...
Americans are increasingly demanding that chemicals and toxic food dyes be removed from items they consume, clean with, wear, ...
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for ...
These recent food recalls involve cream cheese, eggs, shrimp, and ice cream due to serious health risks including salmonella ...
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results